Serono Taps Aussie Biotech For New MS Drugs
This article was originally published in PharmAsia News
Executive Summary
Building its base in multiple sclerosis and related disorders, Merck Serono has sealed a deal with Bionomics to develop the Australian biotech's library of compounds inhibiting the potassium channel Kv1.3